Literature DB >> 21107317

A concise display of multiple end points for benefit-risk assessment.

B Levitan1.   

Abstract

The assessment and representation of benefit-risk "balance" in pharmaceutical development have become increasingly important. Although the methodologies may vary considerably in complexity, most approaches to benefit-risk assessment require the simultaneous consideration of information pertaining to multiple end points for multiple treatments. However, the lengthy data tables and displays that are frequently used make this assessment difficult. Using an example from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, this note presents a conceptually simple visualization that facilitates understanding of information on multiple points.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107317     DOI: 10.1038/clpt.2010.251

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.

Authors:  Bennett Levitan; Michael Markowitz; Ibrahim Turkoz; Dong-Jing Fu; Srihari Gopal; Larry Alphs
Journal:  Int Clin Psychopharmacol       Date:  2016-11       Impact factor: 1.659

2.  Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.

Authors:  Holland C Detke; John Lauriello; John Landry; David P McDonnell
Journal:  Int J Methods Psychiatr Res       Date:  2014-07-03       Impact factor: 4.035

3.  Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.

Authors:  Eva G Katz; David Hough; Teodora Doherty; Rosanne Lane; Jaskaran Singh; Bennett Levitan
Journal:  Clin Pharmacol Ther       Date:  2020-10-13       Impact factor: 6.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.